Restricted accessResearch articleFirst published online 2015-1
Effects of Upstream Administration of Tirofiban Before Percutaneous Coronary Intervention on Spontaneous Reperfusion and Clinical Outcomes in Acute ST-Segment Elevation Myocardial Infarction
We assessed the effects of upstream administration of the glycoprotein IIb/IIIa inhibitor tirofiban before percutaneous coronary intervention (PCI) on spontaneous reperfusion (SR) of infarct-related artery (IRA) and the clinical outcomes in patients with ST-segment elevation myocardial infarction (STEMI). The incidence of SR of the IRA was significantly higher in the tirofiban group than in the no-tirofiban group (141 [36.5%] vs 21 [17.2%], P < .001). By multivariate logistic regression analysis, use of tirofiban (odds ratio 2.32, 95% confidence interval 1.25-4.31, P = .008) independently predicted the occurrence of SR. Kaplan-Meier survival analysis demonstrated that major adverse cardiovascular event-free survival was significantly higher in patients treated with tirofiban than in patients without tirofiban at 30-day (log rank = 11.65, P = .001) and 90-day follow-up (log rank = 16.79, P < .001). Upstream administration of tirofiban is significantly associated with increased SR of the IRA and favorable clinical prognosis in patients undergoing PCI for STEMI.
StegPGJamesSKAtarD. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33(20):2569–2619.
2.
LeeCWHongMKLeeJH. Determinants and prognostic significance of spontaneous coronary recanalization in acute myocardial infarction. Am J Cardiol. 2001;87(8):951–954.
3.
RimarDCrystalEBattlerA. Improved prognosis of patients presenting with clinical markers of spontaneous reperfusion during acute myocardial infarction. Heart. 2002;88(4):352–356.
4.
StoneGWCoxDGarciaE. Normal flow (TIMI-3) before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction: analysis from the primary angioplasty in myocardial infarction trials. Circulation. 2001;104(6):636–641.
5.
BrenerSJMehranRBrodieBR. Predictors and implications of coronary infarct artery patency at initial angiography in patients with acute myocardial infarction (from the CADILLAC and HORIZONS-AMI Trials). Am J Cardiol. 2011;108(7):918–923.
6.
De LucaGSuryapranataHStoneGW. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA. 2005;293(14):1759–1765.
7.
van den MerkhofLFZijlstraFOlssonH. Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty. results of the glycoprotein receptor antagonist patency evaluation (GRAPE) pilot study. J Am CollCardiol. 1999;33(6):1528–1532.
8.
CutlipDECoveCJIronsD. Emergency room administration of eptifibatide before primary angioplasty for ST elevation acute myocardial infarction and its effect on baseline coronary flow and procedure outcomes. Am J Cardiol. 2001;88(1):A6, 62–64.
9.
MontalescotGBarraganPWittenbergO. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med. 2001;344(25):1895–1903.
10.
The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. Circulation. 1997;96(5):1445–1453.
11.
TIMI Study Group. The thrombolysis in myocardial infarction (TIMI) trial. Phase I findings. N Engl J Med. 1985;312(14):932–936.
12.
RentropKPFeitFShermanWThorntonJC. Serial angiographic assessment of coronary artery obstruction and collateral flow in acute myocardial infarction. report from the second Mount Sinai-New York university reperfusion trial. Circulation. 1989;80(5):1166–1175.
13.
BovillEGTerrinMLStumpDC. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. results of the thrombolysis in myocardial infarction (TIMI), phase II trial. Ann Intern Med. 1991;115(4):256–265.
14.
FeferPHodHHammermanH. Relation of clinically defined spontaneous reperfusion to outcome in ST-elevation myocardial infarction. Am J Cardiol. 2009;103(2):149–153.
15.
TerkelsenCJNorgaardBLLassenJF. Potential significance of spontaneous and interventional ST-changes in patients transferred for primary percutaneous coronary intervention: observations from the ST-MONitoring in Acute Myocardial Infarction study (The MONAMI study). Eur Heart J. 2006;27(3):267–275.
16.
CremerPNagelDLabrotB. Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective gottingen risk incidence and prevalence study (GRIPS). Eur J Clin Invest. 1994;24(7):444–453.
17.
TchengJEKandzariDEGrinesCL. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the controlled abciximab and device investigation to lower late angioplasty complications (CADILLAC) trial. Circulation. 2003;108(11):1316–1323.
18.
LeeDPHerityNAHiattBL. Adjunctive platelet glycoprotein IIb/IIIa receptor inhibition with tirofiban before primary angioplasty improves angiographic outcomes: results of the tirofiban given in the emergency room before primary angioplasty (TIGER-PA) pilot trial. Circulation. 2003;107(11):1497–1501.
19.
De LucaGSmitJJErnstN. Impact of adjunctive tirofiban administration on myocardial perfusion and mortality in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction. Thromb Haemost. 2005;93(5):820–823.
20.
HeitzerTOllmannIKokeKMeinertzTMunzelT. Platelet glycoprotein IIb/IIIa receptor blockade improves vascular nitric oxide bioavailability in patients with coronary artery disease. Circulation. 2003;108(5):536–541.
21.
BaineyKRFuYWagnerGS. Spontaneous reperfusion in ST-elevation myocardial infarction: comparison of angiographic and electrocardiographic assessments. Am Heart J. 2008;156(2):248–255.
22.
LangSHManningNArmstrongN. Treatment with tirofiban for acute coronary syndrome (ACS): a systematic review and network analysis. Curr Med Res Opin. 2012;28(3):351–370.
23.
StoneGWWitzenbichlerBGuagliumiG. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008;358(21):2218–2230.
24.
van 't HofAWErnstNde BoerMJ. Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor: results of the ongoing tirofiban in myocardial infarction evaluation (On-TIME) trial. Eur Heart J. 2004;25(10):837–846.
25.
JagroopIAMikhailidisDP. The effect of tirofiban on fibrinogen/agonist- induced platelet shape change and aggregation. Clin Appl Thromb Hemost. 2008;14(3):295–302.
26.
MontalescotGBorentainMPayotLColletJPThomasD. Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis. JAMA. 2004;292(3):362–366.
27.
TopolEJMoliternoDJHerrmannHC. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med. 2001;344(25):1888–1894.
28.
Van't HofAWTen BergJHeestermansT. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial. Lancet. 2008;372(9638):537–546.
29.
ChenSMHsiehYKGuoGB. Angiographic and clinical outcome in ST-segment elevation myocardial infarction patients receiving an adjunctive double bolus regimen of tirofiban for primary percutaneous coronary intervention. Circ J. 2006;70(5):536–541.
30.
BilselTAkbulutTYesilcimenK. Single high-dose bolus tirofiban with high-loading-dose clopidogrel in primary coronary angioplasty. Heart Vessels. 2006;21(2):102–107.
31.
SchneiderDJHerrmannHCLakkisN. Enhanced early inhibition of platelet aggregation with an increased bolus of tirofiban. Am J Cardiol. 2002;90(12):1421–1423.
